TAKE Solutions Announces Global Release of PharmaReady 5.0
TAKE Solutions Ltd.
announced the availability of PharmaReadyTM 5.0, a web-based regulatory compliance solution suite for Life Science organizations to ensure faster approvals for their new products. The latest version introduces new document management features, and delivers technology framework upgrades to enhance scalability, response time, and ease-of-use.
PharmaReady 5.0 supports submissions to Swissmedic (in addition to US FDA, Health Canada and EMEA). It comes with an improved dashboard for easier navigation and management of documents from a centralized location, provides more visibility and control of e-document/e-submission processes, and introduces new functionalities including drag and drop for quicker document uploads. In addition, PharmaReady 5.0 includes an enhanced, highly scalable technology framework allowing the suite to run seamlessly on any Microsoft platform.
Speaking on the occasion, Ram Yeleswarapu, President and CEO, TAKE Solutions, said, “TAKE Solutions has understood the pulse of the life sciences market and has worked persistently towards achieving the goal of better value to our customers. Having used both our IT expertise, as well as our domain knowledge, we are proud to release the upgraded version PharmaReady 5.0” He added, “PharmaReady is a stable and growing product line that has been consistently delivering value to our customers across the globe.”
“TAKE is committed to diligently listening to our customers as well as regulators, partners, and competitors,” stated Mike Lewis, Vice President –Life Sciences, TAKE Solutions. “This release is a key milestone marking our continuous efforts to add value and bring significant and relevant global regulatory standards to our life sciences customer base by acting as a key liaison, thought-leader, and solution provider in this space.”
The PharmaReady solution suite is designed specifically for management of SOPs,work instructions, training records, document and submission publishing in the eCTD and other formats, as well as to manage other electronic documents. PharmaReady is in full compliance with global regulatory requirements and was designed to be an easy to use, easy to deploy, and affordable solution.
PharmaReady has a record of 100% submission acceptance by regulatory authorities, and this is attributed to four key factors: comprehensive solution that meets the latest requirements, out-of-the-box implementation with minimum start-up time, compliance enabled, and a top-notch support team.
Pharmaready has a no. of global customers including Pharmaceutical, Medical device Companies, and CROs. A majority of regulatory submissions by Indian Pharma manufacturers are done using Pharmaready products or related services from TAKE.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
